Header Logo

Connection

MURALI CHINTAGUMPALA to Adult

Back to Details
This is a "connection" page, showing publications MURALI CHINTAGUMPALA has written about Adult.
MURALI CHINTAGUMPALA
Connection Strength
0.371
Adult
  1. A single-arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children's Oncology Group study (ARET 0231). Pediatr Blood Cancer. 2020 09; 67(9):e28502.
    View in: PubMed
    Score: 0.042
  2. Leukaemia & cancer in neonates. Semin Fetal Neonatal Med. 2012 Aug; 17(4):183-184.
    View in: PubMed
    Score: 0.024
  3. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. J Neurooncol. 2006 Apr; 77(2):193-8.
    View in: PubMed
    Score: 0.016
  4. Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol. 2004 Nov 01; 22(21):4394-400.
    View in: PubMed
    Score: 0.014
  5. The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
    View in: PubMed
    Score: 0.014
  6. Late-onset lymphopenia during radiation is associated with an increased risk of tumor recurrence in newly diagnosed pediatric medulloblastoma. Pediatr Blood Cancer. 2024 Jul; 71(7):e31022.
    View in: PubMed
    Score: 0.014
  7. Prognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience. J Neurooncol. 2023 Jul; 163(3):717-726.
    View in: PubMed
    Score: 0.013
  8. Multi-institutional Characterization of Outcomes for Pediatric and Young Adult Patients With High-Risk Myxopapillary Ependymoma After Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023 Dec 01; 117(5):1174-1180.
    View in: PubMed
    Score: 0.013
  9. Characteristics of patients =10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro Oncol. 2022 01 05; 24(1):141-152.
    View in: PubMed
    Score: 0.012
  10. Maternal and perinatal factors are associated with risk of pediatric central nervous system tumors and poorer survival after diagnosis. Sci Rep. 2021 05 17; 11(1):10410.
    View in: PubMed
    Score: 0.011
  11. Development of second primary tumors and outcomes in medulloblastoma by treatment modality: A Surveillance, Epidemiology, and End Results analysis. Pediatr Blood Cancer. 2020 08; 67(8):e28373.
    View in: PubMed
    Score: 0.010
  12. Effect of sensorineural hearing loss on neurocognitive and adaptive functioning in survivors of pediatric embryonal brain tumor. J Neurooncol. 2020 Jan; 146(1):147-156.
    View in: PubMed
    Score: 0.010
  13. Cognitive mediators of adaptive functioning outcomes in survivors of pediatric brain tumors treated with proton radiotherapy. Pediatr Blood Cancer. 2020 02; 67(2):e28064.
    View in: PubMed
    Score: 0.010
  14. Adaptive functioning in pediatric brain tumor survivors: An examination of ethnicity and socioeconomic status. Pediatr Blood Cancer. 2019 09; 66(9):e27800.
    View in: PubMed
    Score: 0.010
  15. Gastrointestinal autonomic nerve tumors in the pediatric population: a report of four cases and a review of the literature. Cancer. 1999 Jan 01; 85(1):220-30.
    View in: PubMed
    Score: 0.009
  16. Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol. 2018 07 01; 36(19):1963-1972.
    View in: PubMed
    Score: 0.009
  17. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018 06; 19(6):785-798.
    View in: PubMed
    Score: 0.009
  18. Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group. Ann Surg. 2017 09; 266(3):470-478.
    View in: PubMed
    Score: 0.009
  19. Mixed neuronal-glial tumors (gangliogliomas) in children. Pediatr Neurosurg. 1996 Jun; 24(6):306-13.
    View in: PubMed
    Score: 0.008
  20. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015 Aug 20; 33(24):2646-54.
    View in: PubMed
    Score: 0.007
  21. Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer. J Neurosurg Pediatr. 2015 Jul; 16(1):4-13.
    View in: PubMed
    Score: 0.007
  22. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatr Blood Cancer. 2014 Apr; 61(4):601-5.
    View in: PubMed
    Score: 0.007
  23. Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas. Neuro Oncol. 2013 Jun; 15(6):759-66.
    View in: PubMed
    Score: 0.006
  24. Maternal variation in EPHX1, a xenobiotic metabolism gene, is associated with childhood medulloblastoma: an exploratory case-parent triad study. Pediatr Hematol Oncol. 2012 Nov; 29(8):679-85.
    View in: PubMed
    Score: 0.006
  25. Outcome of patients with pilocytic astrocytoma and leptomeningeal dissemination. Int J Radiat Oncol Biol Phys. 2012 Oct 01; 84(2):350-4.
    View in: PubMed
    Score: 0.006
  26. Plasma proteome predicts chemotherapy response in osteosarcoma patients. Oncol Rep. 2011 Feb; 25(2):303-14.
    View in: PubMed
    Score: 0.005
  27. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008 Aug 01; 26(22):3749-55.
    View in: PubMed
    Score: 0.005
  28. Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997. Pediatr Blood Cancer. 2008 May; 50(5):958-64.
    View in: PubMed
    Score: 0.005
  29. Intensity-modulated radiation therapy in childhood ependymoma. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):987-93.
    View in: PubMed
    Score: 0.004
  30. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys. 2008 Mar 01; 70(3):782-7.
    View in: PubMed
    Score: 0.004
  31. Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival. J Neurooncol. 2008 Jan; 86(2):183-90.
    View in: PubMed
    Score: 0.004
  32. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006 Oct; 7(10):813-20.
    View in: PubMed
    Score: 0.004
  33. Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics. 2006 Jun; 6(11):3426-35.
    View in: PubMed
    Score: 0.004
  34. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006 Apr 20; 24(12):1924-31.
    View in: PubMed
    Score: 0.004
  35. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol. 2006 Feb; 76(3):313-9.
    View in: PubMed
    Score: 0.004
  36. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005 Sep 15; 65(18):8142-50.
    View in: PubMed
    Score: 0.004
  37. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. 2005 Aug 20; 23(24):5511-9.
    View in: PubMed
    Score: 0.004
  38. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol. 2004 Aug 15; 22(16):3357-65.
    View in: PubMed
    Score: 0.003
  39. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst. 2003 May 07; 95(9):669-74.
    View in: PubMed
    Score: 0.003
  40. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. Cancer. 2003 May 01; 97(9 Suppl):2374-80.
    View in: PubMed
    Score: 0.003
  41. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res. 2002 Jul; 8(7):2202-9.
    View in: PubMed
    Score: 0.003
  42. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet. 2001 Jul 22; 102(1):11-7.
    View in: PubMed
    Score: 0.003
  43. Surgery for ovarian masses in infants, children, and adolescents: 102 consecutive patients treated in a 15-year period. J Pediatr Surg. 2001 May; 36(5):693-9.
    View in: PubMed
    Score: 0.003
  44. Neoplasms in neurofibromatosis 1 are related to gender but not to family history of cancer. Genet Epidemiol. 2001 Jan; 20(1):75-86.
    View in: PubMed
    Score: 0.003
  45. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol. 1998 Apr; 57(4):293-302.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.